Shares of VIVUS (VVUS +0.00%) were up 10.5% today, after news that sales were up for November for the company's obesity drug, Qsymia. This may suggest that some of the company's new marketing strategies for the drug may be turning sluggish sales around. But is the drug finally gaining momentum, or is it just a volatile cyclical stock at the moment? Motley Fool health care analyst Max Macaluso gives us his thoughts on how and when we'll know where VIVUS is headed.
Hold Your Horses, VIVUS Investors
By Max Macaluso and Dave Williamson – Dec 17, 2012 at 7:15PM
NASDAQ: VVUS
Vivus
Another pop from VIVUS today, but will it last?
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo